Melanoma research gets a funding boost from NHMRC
9 December 2016
Research projects led by Melanoma Institute Australia (MIA) have been awarded almost $6 million in the latest National Health and Medical Research Council (NHMRC) funding round which will enable vital progression of research into melanoma prevention and treatment. Projects led by MIA researchers have been awarded the highly competitive funding:
- Professor Georgina Long (MIA and The University of Sydney) received a Practitioner Fellowship (5 years) to investigate the underlying biology of patients’ responses to treatment. By understanding why some patients respond well to therapies when others develop resistance will help us develop tests to ensure the best possible treatment is given to each individual patient. In addition, it will also help identify the ideal drug therapy combinations to improve patient outcomes further or prevent metastatic melanoma altogether.
- Professor Nicholas Hayward (MIA and QIMR Berghofer) received a Research Fellowship (3 years) to investigate genetic predisposition to melanoma in the general population and predisposed families, and the genes involved in traits underlying melanoma development. He was also awarded a Project Grant (5 years) to conduct a comprehensive genetic analysis of acral melanoma to ultimately identify new drug targets to treat this disease. Although an uncommon subtype of melanoma, acral melanoma has a bad prognosis and has been poorly characterised at the molecular level.
- Professor Helen Rizos (MIA and Macquarie University) received two Project Grants to investigate the cell biology of melanoma. These project grants involved a team of chief investigators from MIA, who have collaborated on melanoma response and resistance for many years, including Professor Richard Kefford, Professor Georgina Long, Dr Matteo Carlino, Dr Alexander Menzies and Dr Xu Dong Zhang, and new collaborator Professor Barbara Fazekas de St Groth. The first Project Grant (4 years) will be used to investigate the mechanisms of response and resistance to combination immunotherapies in order to enhance the duration and rate of patient response. The second Project Grant (4 years) will use tumour samples of patients who have developed resistance to immunotherapies to determine the underlying mechanisms involved. This information will accelerate the identification of new combination therapies to improve patient outcomes.
- Associate Professor Anne Cust (MIA and The University of Sydney) was awarded a 4-year Project Grant to improve skin cancer prevention. Her research will evaluate whether they can improve skin cancer prevention behaviours by giving personalised information about melanoma genetic risk. They will also explore the psycho-social, ethical and economic implications of receiving this information, with the ultimate aim to positively influence the future of skin cancer prevention in Australia.
To date, the 2016 NHMRC Grant Application Round has resulted in the commitment of more than $703 million to fund health and medical research across Australia.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.